Drug Profile
V 0162
Alternative Names: V0162; VO-162Latest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Developer Pierre Fabre; SGS
- Class Phenothiazines; Small molecules
- Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Overactive bladder; Urinary incontinence
Most Recent Events
- 27 Aug 2019 Discontinued - Clinical-Phase-Unknown for Overactive bladder in Poland (Vaginal) (Pierre Fabre website - August 2019)
- 27 Aug 2019 Discontinued - Phase-I/II for Chronic obstructive pulmonary disease in Belgium (Inhalation) (Pierre Fabre website - August 2019)
- 27 Aug 2019 Discontinued - Phase-I/II for Chronic obstructive pulmonary disease in France (Inhalation) (Pierre Fabre website - August 2019)